Jan 14 (Reuters) – British cell and gene therapy manufacturer Oxford Biomedica confirmed on Wednesday that it has received an unsolicited cash offer from funds managed by EQT for all of its shares. The group, which is in preliminary discussions regarding the potential all-cash offer, added that it had previously rejected unsolicited proposals from EQT. EQT […]
Health
UK’s Oxford Biomedica confirms unsolicited bid from funds managed by EQT
Audio By Carbonatix
Jan 14 (Reuters) – British cell and gene therapy manufacturer Oxford Biomedica confirmed on Wednesday that it has received an unsolicited cash offer from funds managed by EQT for all of its shares.
The group, which is in preliminary discussions regarding the potential all-cash offer, added that it had previously rejected unsolicited proposals from EQT.
EQT has a February 11 deadline to make a firm offer for the group or walk away, according to Oxford Biomedica’s statement.
Oxford Biomedica, which provides contracting services to pharmaceutical firms, reported total revenue of 73.2 million pounds ($98.40 million) for the six months ended June 30, 2025.
($1 = 0.7439 pounds)
(Reporting by Unnamalai L in Bengaluru; Editing by Alan Barona)